WEBULL
News
CCCC
1.820
+6.43%
0.110
Weekly Report: what happened at CCCC last week (0126-0130)?
Weekly Report · 6d ago
BRIEF-C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule
Reuters · 01/26 21:29
C4 Therapeutics Grants Stock Options to New Employee as Inducement
Reuters · 01/26 21:01
Weekly Report: what happened at CCCC last week (0119-0123)?
Weekly Report · 01/26 10:05
After Hours Most Active for Jan 20, 2026 : NFLX, AAPL, NVDA, T, CCCC, F, PFE, WMT, INTC, GPN, PATH, NUVB
NASDAQ · 01/21 00:59
C4 Therapeutics Unveils Pipeline Strategy Focused on Protein Degraders for Oncology and Inflammatory Diseases
Reuters · 01/20 12:12
Weekly Report: what happened at CCCC last week (0112-0116)?
Weekly Report · 01/19 10:10
Top C4 Therapeutics Executive Makes Notable Move With Company Shares
TipRanks · 01/17 02:01
C4 Therapeutics Chief Medical Officer Leonard Reyno Reports Sale of Common Shares
Reuters · 01/16 21:28
C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors
TipRanks · 01/15 16:34
C4 Therapeutics Unveils Multi-Year Cemsidomide Clinical Strategy
TipRanks · 01/14 12:28
C4 Therapeutics Positions Cemsidomide As Potential Best-In-Class Myeloma Therapy While Expanding Discovery Efforts Beyond Oncology
Benzinga · 01/14 12:08
C4 Therapeutics Announces Plans to Advance Cemsidomide Through Phase 2 Trials, Initiate Combination Studies, and Expand Discovery Pipeline Targeting Inflammation and Neurodegenerative Diseases Through 2028
Reuters · 01/14 12:00
C4 Therapeutics Sets Up New Combination Trial in Multiple Myeloma: What Investors Should Watch
TipRanks · 01/12 16:32
Weekly Report: what happened at CCCC last week (0105-0109)?
Weekly Report · 01/12 10:09
Weekly Report: what happened at CCCC last week (1229-0102)?
Weekly Report · 01/05 10:04
Weekly Report: what happened at CCCC last week (1222-1226)?
Weekly Report · 12/29/2025 10:04
Weekly Report: what happened at CCCC last week (1215-1219)?
Weekly Report · 12/22/2025 10:03
After Hours Most Active for Dec 18, 2025 : BAC, C, NVDA, CCCC, GRAB, RXRX, AAPL, QQQ, COMP, PCG, PGRE, NU
NASDAQ · 12/18/2025 21:18
Evercore ISI Remains a Buy on C4 Therapeutics (CCCC)
TipRanks · 12/18/2025 11:56
More
Webull provides a variety of real-time CCCC stock news. You can receive the latest news about C4 Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CCCC
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).